OUTLOOK THERAPEUTICS, INC. Net Income
OUTLOOK THERAPEUTICS, INC. (OTLK) reported Net Income of -$20.32 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-18.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-18
- OUTLOOK THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$20.32M.
- OUTLOOK THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$4.45M.
- OUTLOOK THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$23.06M, a 232.69% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$13.29M, a 333.56% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2025 was -$62.42M.
- OUTLOOK THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2024 was -$75.37M.
- OUTLOOK THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2023 was -$58.98M.
- OUTLOOK THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2022 was -$66.05M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$20.32M 10-Q · filed 2026-08-18 | -$24.77M derived: sum of 2 quarters · filed 2026-08-18 | -$47.83M 10-Q · filed 2026-08-18 | -$61.12M derived: sum of 4 quarters · filed 2026-08-18 | ||||
| 2026-03-31 | -$4.45M 10-Q · filed 2026-08-18 | -$27.51M 10-Q · filed 2026-05-15 | -$40.80M derived: sum of 3 quarters · filed 2026-08-18 | -$60.96M derived: sum of 4 quarters · filed 2026-08-18 | ||||
| 2025-12-31 | -$23.06M 10-Q · filed 2026-08-18 | -$36.35M derived: sum of 2 quarters · filed 2026-08-18 | -$56.50M derived: sum of 3 quarters · filed 2026-08-18 | -$102.86M derived: sum of 4 quarters · filed 2026-08-18 | ||||
| 2025-09-30 | -$13.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-19 | -$33.45M derived: sum of 2 quarters · filed 2026-08-18 | -$79.80M derived: sum of 3 quarters · filed 2026-08-18 | -$62.42M 10-K · filed 2025-12-19 | ||||
| 2025-06-30 | -$20.15M 10-Q · filed 2026-08-18 | -$66.51M derived: sum of 2 quarters · filed 2026-08-18 | -$49.13M 10-Q · filed 2026-08-18 | -$43.44M derived: sum of 4 quarters · filed 2026-08-18 | ||||
| 2025-03-31 | -$46.36M 10-Q · filed 2026-08-18 | -$28.98M 10-Q · filed 2026-05-15 | -$23.29M derived: sum of 3 quarters · filed 2026-08-18 | $21.12M derived: sum of 4 quarters · filed 2026-08-18 | ||||
| 2024-12-31 | $17.38M 10-Q · filed 2026-08-18 | $23.07M derived: sum of 2 quarters · filed 2026-08-18 | $67.48M derived: sum of 3 quarters · filed 2026-08-18 | -$46.81M derived: sum of 4 quarters · filed 2026-08-18 | ||||
| 2024-09-30 | $5.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-19 | $50.10M derived: sum of 2 quarters · filed 2025-12-19 | -$64.19M derived: sum of 3 quarters · filed 2025-12-19 | -$75.37M 10-K · filed 2025-12-19 | ||||
| 2024-06-30 | $44.41M 10-Q · filed 2025-08-14 | -$69.88M derived: sum of 2 quarters · filed 2025-08-14 | -$81.06M 10-Q · filed 2025-08-14 | -$94.05M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | -$114.29M 10-Q · filed 2025-08-14 | -$125.47M 10-Q · filed 2025-05-15 | -$138.46M derived: sum of 3 quarters · filed 2025-08-14 | -$159.13M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2023-12-31 | -$11.18M 10-Q · filed 2025-08-14 | -$24.17M derived: sum of 2 quarters · filed 2025-08-14 | -$44.84M derived: sum of 3 quarters · filed 2025-08-14 | -$51.50M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2023-09-30 | -$12.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-27 | -$33.67M derived: sum of 2 quarters · filed 2024-12-27 | -$40.32M derived: sum of 3 quarters · filed 2024-12-27 | -$58.98M 10-K · filed 2024-12-27 | ||||
| 2023-06-30 | -$20.68M 10-Q · filed 2024-08-14 | -$27.33M derived: sum of 2 quarters · filed 2024-08-14 | -$45.99M 10-Q · filed 2024-08-14 | -$60.34M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | -$6.65M 10-Q · filed 2024-08-14 | -$25.32M 10-Q · filed 2024-05-15 | -$39.66M derived: sum of 3 quarters · filed 2024-08-14 | -$57.20M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2022-12-31 | -$18.66M 10-Q · filed 2024-08-14 | -$33.01M derived: sum of 2 quarters · filed 2024-08-14 | -$50.55M derived: sum of 3 quarters · filed 2024-08-14 | -$70.25M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2022-09-30 | -$14.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-22 | -$31.88M derived: sum of 2 quarters · filed 2023-12-22 | -$51.59M derived: sum of 3 quarters · filed 2023-12-22 | -$66.05M 10-K · filed 2023-12-22 | ||||
| 2022-06-30 | -$17.54M 10-Q · filed 2023-08-14 | -$37.24M derived: sum of 2 quarters · filed 2023-08-14 | -$51.71M 10-Q · filed 2023-08-14 | -$65.11M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | -$19.70M 10-Q · filed 2023-08-14 | -$34.17M 10-Q · filed 2023-05-15 | -$47.57M derived: sum of 3 quarters · filed 2023-08-14 | -$59.77M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2021-12-31 | -$14.46M 10-Q · filed 2023-08-14 | -$27.87M derived: sum of 2 quarters · filed 2023-08-14 | -$40.06M derived: sum of 3 quarters · filed 2023-08-14 | -$53.17M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2021-09-30 | -$13.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-29 | -$25.60M derived: sum of 2 quarters · filed 2022-12-29 | -$38.71M derived: sum of 3 quarters · filed 2022-12-29 | -$53.16M 10-K · filed 2022-12-29 | ||||
| 2021-06-30 | -$12.20M 10-Q · filed 2022-08-10 | -$25.30M derived: sum of 2 quarters · filed 2022-08-10 | -$39.76M 10-Q · filed 2022-08-10 | -$49.68M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | -$13.11M 10-Q · filed 2022-08-10 | -$27.56M 10-Q · filed 2022-05-13 | -$37.48M derived: sum of 3 quarters · filed 2022-08-10 | -$40.50M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2020-12-31 | -$14.46M 10-Q · filed 2022-08-10 | -$24.38M derived: sum of 2 quarters · filed 2022-08-10 | -$27.39M derived: sum of 3 quarters · filed 2022-08-10 | -$33.09M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2020-09-30 | -$9.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-23 | -$12.94M derived: sum of 2 quarters · filed 2021-12-23 | -$18.64M derived: sum of 3 quarters · filed 2021-12-23 | -$35.24M 10-K · filed 2021-12-23 | ||||
| 2020-06-30 | -$3.01M 10-Q · filed 2021-08-13 | -$8.71M derived: sum of 2 quarters · filed 2021-08-13 | -$25.32M 10-Q · filed 2021-08-13 | -$35.41M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | -$5.70M 10-Q · filed 2021-05-14 | -$22.30M 10-Q · filed 2021-05-14 | -$32.40M derived: sum of 3 quarters · filed 2021-05-14 | -$36.84M derived: sum of 4 quarters · filed 2021-05-14 | ||||
| 2019-12-31 | -$16.60M 10-Q · filed 2021-02-16 | -$26.70M derived: sum of 2 quarters · filed 2021-02-16 | -$31.14M derived: sum of 3 quarters · filed 2021-02-16 | -$41.38M derived: sum of 4 quarters · filed 2021-02-16 | ||||
| 2019-09-30 | -$10.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-23 | -$14.54M derived: sum of 2 quarters · filed 2020-12-23 | -$24.78M derived: sum of 3 quarters · filed 2020-12-23 | -$34.52M 10-K · filed 2020-12-23 | ||||
| 2019-06-30 | -$4.44M 10-Q · filed 2020-08-14 | -$14.69M derived: sum of 2 quarters · filed 2020-08-14 | -$24.43M 10-Q · filed 2020-08-14 | -$36.63M derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2019-03-31 | -$10.24M 10-Q · filed 2020-05-15 | -$19.99M 10-Q · filed 2020-05-15 | -$32.19M derived: sum of 3 quarters · filed 2020-05-15 | -$40.62M derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | -$9.74M 10-Q · filed 2020-02-14 | -$21.94M derived: sum of 2 quarters · filed 2020-02-14 | -$30.37M derived: sum of 3 quarters · filed 2020-02-14 | -$37.91M derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-09-30 | -$12.20M derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-19 | -$20.63M derived: sum of 2 quarters · filed 2019-12-19 | -$28.17M derived: sum of 3 quarters · filed 2019-12-19 | -$30.09M 10-K · filed 2019-12-19 | ||||
| 2018-06-30 | -$8.43M 10-Q · filed 2019-08-14 | -$15.97M derived: sum of 2 quarters · filed 2019-08-14 | -$17.89M 10-Q · filed 2019-08-14 | -$24.27M derived: sum of 4 quarters · filed 2019-08-14 | ||||
| 2018-03-31 | -$7.54M 10-Q · filed 2019-05-15 | -$9.46M 10-Q · filed 2019-05-15 | -$15.83M derived: sum of 3 quarters · filed 2019-05-15 | -$21.17M derived: sum of 4 quarters · filed 2019-05-15 | ||||
| 2017-12-31 | -$1.92M 10-Q · filed 2019-02-14 | -$8.29M derived: sum of 2 quarters · filed 2019-02-14 | -$13.63M derived: sum of 3 quarters · filed 2019-02-14 | -$21.67M derived: sum of 4 quarters · filed 2019-02-14 | ||||
| 2017-09-30 | -$6.37M derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-18 | -$11.70M derived: sum of 2 quarters · filed 2018-12-18 | -$19.75M derived: sum of 3 quarters · filed 2018-12-18 | -$38.85M 10-K · filed 2018-12-18 | ||||
| 2017-06-30 | -$5.33M 10-Q · filed 2018-08-14 | -$5.33M 10-Q · filed 2017-08-14 | -$13.38M derived: sum of 2 quarters · filed 2018-08-14 | -$32.48M 10-Q · filed 2018-08-14 | -$32.47M 10-Q · filed 2017-08-14 | -$43.04M derived: sum of 4 quarters · filed 2018-08-14 | ||
| 2017-03-31 | -$8.05M 10-Q · filed 2018-05-15 | -$8.04M 10-Q · filed 2017-05-15 | -$27.14M 10-Q · filed 2018-05-15 | -$27.14M 10-Q · filed 2017-05-15 | -$37.71M derived: sum of 3 quarters · filed 2018-05-15 | -$60.04M derived: sum of 4 quarters · filed 2018-05-15 | ||
| 2016-12-31 | -$19.10M 10-Q · filed 2018-02-14 | -$19.10M 10-Q · filed 2017-02-14 | -$29.67M derived: sum of 2 quarters · filed 2018-02-14 | -$51.99M derived: sum of 3 quarters · filed 2018-02-14 | -$55.54M derived: sum of 4 quarters · filed 2018-02-14 | |||
| 2016-09-30 | -$10.57M derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-29 | -$32.90M derived: sum of 2 quarters · filed 2017-12-29 | -$36.44M derived: sum of 3 quarters · filed 2017-12-29 | -$53.30M 10-K · filed 2017-12-29 | -$53.33M 10-K · filed 2016-12-29 | |||
| 2016-06-30 | -$22.33M 10-Q · filed 2017-08-14 | -$25.87M derived: sum of 2 quarters · filed 2017-08-14 | -$42.73M 10-Q · filed 2017-08-14 | -$59.90M derived: sum of 4 quarters · filed 2017-08-14 | ||||
| 2016-03-31 | -$3.54M 10-Q · filed 2017-05-15 | -$20.41M 10-Q · filed 2017-05-15 | -$37.57M derived: sum of 3 quarters · filed 2017-05-15 | -$48.91M derived: sum of 4 quarters · filed 2017-05-15 | ||||
| 2015-12-31 | -$16.86M 10-Q · filed 2017-02-14 | -$34.03M derived: sum of 2 quarters · filed 2017-02-14 | -$45.37M derived: sum of 3 quarters · filed 2017-02-14 | -$59.35M derived: sum of 4 quarters · filed 2017-02-14 | ||||
| 2015-09-30 | -$17.16M derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-29 | -$28.50M derived: sum of 2 quarters · filed 2016-12-29 | -$42.49M derived: sum of 3 quarters · filed 2016-12-29 | -$47.39M 10-K · filed 2016-12-29 | ||||
| 2015-06-30 | -$11.34M 10-Q · filed 2016-08-15 | -$25.32M derived: sum of 2 quarters · filed 2016-08-15 | -$30.23M 10-Q · filed 2016-08-15 | |||||
| 2015-03-31 | -$13.98M 10-Q · filed 2016-06-27 | -$18.89M 10-Q · filed 2016-06-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |